Key points are not available for this paper at this time.
Renal cell carcinoma (RCC) is the most common kidney disorder, representing 2-3% of all cancers. Originally from the proximal convoluted tubule, RCC is affected by causes such as smoking, obesity, and genetic mutations, specifically in the von Hippel-Lindau (VHL) gene. These mutations impact tumor growth and metastasis by dysregulating hypoxia-inducible factors (HIFs). Innovations in radiological techniques have increased RCC discoveries, signifying a higher detection in men and peak diagnosis in the 60s. While early onset RCC has a preferable cause of a five-year survival rate of approximately 90%, metastatic RCC (mRCC) presents a significant challenge with less than a 10% survival rate over five years due to its systemic spread. Traditional treatments, including chemotherapy and radiotherapy, have limited efficacy in mRCC. However, immunotherapy has emerged as a critical treatment modality. Non-specific cytokine therapies like interleukin-2 (IL-2) and interferon-alpha (IFN-α) have demonstrated some success but with significant toxicity. Recent developments in checkpoint inhibitors, such as nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), have shown promise in clinical trials, leading to their adoption as standard mRCC treatments. Current research is focused on combination therapies, such as integrating tyrosine kinase inhibitors with checkpoint inhibitors, to enhance therapeutic outcomes. This paper evaluates the efficacy of current immunotherapy treatments in improving survival rates and quality of life for mRCC patients, highlighting the ongoing advancements and future directions in RCC immunotherapy.
Choudhary et al. (Sun,) studied this question.